

For the relief of the pain of osteoarthritis (OA) of joints amenable to topical treatment, such as the knees and those of the hands

NEW Voltaren® Gel

Easy to Dose...

Affected joint	Dosage/ administration	Maximum total grams per day per joint	Total grams per month*	Tubes per month
Lower Extremity: (eg, knee, ankle, or foot)	4 g QID (each joint)	16 g	480 g	5
Upper Extremity: (eg, elbow, wrist, or hand)	2 g QID (each joint)	8 g	240 g	3

Note: Total dosage should not exceed 32 grams per day over all affected joints.

*1 month based on 30 days.

Easy to Prescribe...




Available in 100-gram tubes

Voltaren Gel should not be used in combination with other oral NSAIDs or aspirin because of the potential for increased adverse effects. Similarly, combined use of Voltaren Gel with other topical products, such as sunscreens and cosmetics, on the same skin area has not been tested and should be avoided because of the potential to alter local tolerability and absorption.

NEW
Voltaren® Gel
(diclofenac sodium topical gel) 1% 

Easy to Use...

- Drug carton includes enough dosing cards for duration of treatment



Measure... to the appropriate
2-gram or 4-gram line



Apply... to the affected joint



Rub... over the entire affected
joint, ensuring accurate application

Important Safety Information

Cardiovascular Risk

- Non-steroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
- Voltaren® Gel is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Risk

- NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.

The most common adverse reactions reported in Voltaren Gel clinical trials were application site reactions in 7% of treated patients. With all NSAIDs there may be an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.

The use of Voltaren Gel is contraindicated in patients with a known hypersensitivity to diclofenac.

Voltaren Gel should not be administered to patients who have experienced asthma, urticaria or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

Voltaren Gel is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Please see full Prescribing Information
for Warnings and Contraindications.

Visit www.voltarengel.com for more information

Comments or Questions?
Call toll-free 1-800-452-0051



Marketed by:
Endo Pharmaceuticals, Inc.
Chadds Ford, PA 19317



NOVARTIS

Manufactured for:
Novartis Consumer Health, Inc.
Parsippany, NJ 07054



NOVARTIS

Manufactured by:
Novartis Pharma Productions GmbH
Wehr, Germany

©2008 Novartis Consumer Health, Inc., Parsippany, NJ 07054. All Trademarks owned and licensed by Novartis AG
VG-0002/April 2008 www.voltarengel.com

NEW
Voltaren® Gel
(diclofenac sodium topical gel) 1%

